Dihydroquinazoline-Derived Inhibitors for Alzheimer's Disease Treatment
Researchers at Purdue University have developed novel compounds that inhibit beta-secretase for Alzheimer's treatment. By focusing on a known dihydroquinazoline scaffold, a series of novel dihydroquinazoline derivatives were synthesized and evaluated. Several compounds in this series were shown to exhibit better beta-secretase cellular inhibitory activity compared to current compounds reported in literature. These compounds show increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability.
Improved beta-secretase cellular inhibitionIncreased metabolic stability
Medical/HealthcarePharmaceutical Industry
Arun GhoshGhosh GroupPurdue Chemistry
United States
8,394,807
美国
